Effects of darbepoetin alfa injection: A Synthesis of Findings from 25 Studies

  1. Home
  2. Effects of darbepoetin alfa injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of darbepoetin alfa injection: A Synthesis of Findings from 25 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of darbepoetin alfa injection: A Synthesis of Findings from 25 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Findings

Darbepoetin alfa is a long-acting erythropoiesis-stimulating agent that has shown efficacy in treating anemia in various populations, including those with chronic kidney disease (CKD) and cancer patients undergoing chemotherapy. 20 , 4 , 19 , 24 , 23 , 6 , 11 , 15 , 18 It effectively increases hemoglobin levels and improves anemia-related symptoms. 20 , 4 , 19 , 24 , 23 , 6 , 11 , 15 , 18 Furthermore, it has shown potential benefits in improving lipid metabolism, reducing bilirubin-induced neuronal damage, and aiding in hematopoietic recovery after radiation exposure. 24 , 12 , 9 , 8 However, it is crucial to note that darbepoetin alfa can also cause adverse effects, such as high blood pressure, blood clots, stroke, and heart attack. 17 , 7

Benefits and Risks

Benefits Summary

Darbepoetin alfa offers several benefits, including the treatment of anemia in various patient groups, potential for improved lipid metabolism, reduction in bilirubin-induced neuronal damage, and potential aid in hematopoietic recovery after radiation exposure. 20 , 4 , 19 , 24 , 23 , 6 , 11 , 15 , 18 , 24 , 12 , 9 , 8 Its long-acting nature allows for less frequent administration compared to other erythropoiesis-stimulating agents, enhancing patient convenience. 11 , 16

Risks Summary

Darbepoetin alfa poses potential risks, including high blood pressure, blood clots, stroke, and heart attack. 17 , 7 Dosage adjustments are crucial, and individuals should consult with their healthcare provider to understand and manage these risks. 21

Comparison of Studies

Similarities in Studies

Across several studies, darbepoetin alfa has consistently shown effectiveness in managing anemia, specifically in cases of CKD and chemotherapy-induced anemia. 20 , 4 , 19 , 24 , 23 , 6 , 11 , 15 , 18 Furthermore, its extended half-life offers patients the benefit of less frequent dosing compared to other ESAs, promoting patient adherence and convenience. 11 , 16

Differences in Studies

Studies investigating darbepoetin alfa exhibit variations in their methodology, including patient populations, specific outcomes assessed, and administration methods. 20 , 4 , 19 , 24 , 23 , 6 , 11 , 15 , 18 For instance, different studies may employ subcutaneous or intravenous routes for administration. 4 , 23 Similarly, the patient groups under investigation may vary, encompassing CKD patients, those undergoing chemotherapy, or other specific populations. 20 , 4 , 19 , 24 , 23 , 6 , 11 , 15 , 18

Consistency and Discrepancies in Findings

While multiple studies consistently demonstrate the efficacy of darbepoetin alfa in managing anemia across various populations, there is some discrepancy in the reported adverse effects. 20 , 4 , 19 , 24 , 23 , 6 , 11 , 15 , 18 , 17 , 7 This variability might be attributed to factors such as the study design, patient demographics, and specific endpoints assessed. 20 , 4 , 19 , 24 , 23 , 6 , 11 , 15 , 18 Further research is needed to better understand the potential adverse effects and develop strategies for risk mitigation. 17 , 7

Considerations for Real-World Application

While darbepoetin alfa shows promise in treating anemia, it is essential to acknowledge its potential adverse effects. 20 , 4 , 19 , 24 , 23 , 6 , 11 , 15 , 18 , 17 , 7 Prior to initiating treatment, a thorough discussion with a healthcare professional is crucial to weigh the potential benefits and risks. 20 , 4 , 19 , 24 , 23 , 6 , 11 , 15 , 18 , 17 , 7 Moreover, regular monitoring by a healthcare provider is vital to assess treatment efficacy, manage potential side effects, and make any necessary adjustments to the dosage or treatment plan. 20 , 4 , 19 , 24 , 23 , 6 , 11 , 15 , 18 , 17 , 7

Limitations of Current Research

Darbepoetin alfa research is limited by factors such as small sample sizes, short study durations, and incomplete understanding of long-term effects and safety profiles. 20 , 4 , 19 , 24 , 23 , 6 , 11 , 15 , 18 Therefore, continued research is necessary to address these limitations and gain a more comprehensive understanding of the long-term implications and optimal use of darbepoetin alfa. 20 , 4 , 19 , 24 , 23 , 6 , 11 , 15 , 18

Future Directions for Research

To fully understand the long-term effects and safety of darbepoetin alfa, larger-scale, longer-duration studies are needed. 20 , 4 , 19 , 24 , 23 , 6 , 11 , 15 , 18 Additionally, research focused on minimizing the risk of adverse effects associated with darbepoetin alfa is essential. 17 , 7

Conclusion

Darbepoetin alfa offers a valuable treatment option for anemia in various populations, with the advantage of less frequent dosing compared to other ESAs. 20 , 4 , 19 , 24 , 23 , 6 , 11 , 15 , 18 However, it's crucial to be aware of the potential adverse effects, and to consult with a healthcare professional to weigh the benefits and risks. 17 , 7 Continued research is essential to enhance our understanding of the long-term impacts and optimize the safe and effective use of darbepoetin alfa in clinical practice. 20 , 4 , 19 , 24 , 23 , 6 , 11 , 15 , 18 , 17 , 7

Literature analysis of 25 papers
Positive Content
21
Neutral Content
4
Negative Content
0
Article Type
11
1
1
1
25
1.

Comparison of the pharmacodynamic effects of deflazacort and prednisolone in healthy subjects.

Author: BabadjanovaG, AllolioB, VollmerM, ReinckeM, SchulteH M

Anti-inflammatory
Glucocorticoid
Adverse effects

The study focused on the equipotency ratio of deflazacort versus other glucocorticoids for the assumption of fewer adverse effects.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

2.

Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis.

Author: SarnakMark J, AgarwalRajiv, BoudvilleNeil, ChowdhuryPradip C P, EckardtKai-Uwe, GonzalezCarlos R, KooiengaLaura A, KouryMark J, NtosoKwabena A, LuoWenli, ParfreyPatrick S, VargoDennis L, WinkelmayerWolfgang C, ZhangZhiqun, ChertowGlenn M

Cardiovascular safety
Hematological efficacy
Oral anemia treatment
Unclear peritoneal dialysis effects

This article discusses the use of vadadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, as an oral alternative to injectable erythropoiesis-stimulating agents for treating anemia in patients receiving peritoneal dialysis.

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study.

Author: WaradyBradley A, Meyer ReignerSylvie, TirodkarChitra, DrozdzDorota

C.E.R.A. efficacy
Pediatric anemia treatment

This study investigated the optimal starting dose of subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in pediatric patients with renal anemia. The study found that subcutaneous C.E.R.A. was safe and effective for treating anemia in children, including those not on dialysis. The authors recommend using defined dose-conversion factors to determine the optimal starting dose.

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

Overall Adverse Event Profile of Vadadustat versus Darbepoetin Alfa for the Treatment of Anemia Associated with Chronic Kidney Disease in Phase 3 Trials.

Author: AgarwalRajiv, AnandSanjeev, EckardtKai-Uwe, LuoWenli, ParfreyPatrick S, SarnakMark J, SolinskyChristine M, VargoDennis L, WinkelmayerWolfgang C, ChertowGlenn M

CKD anemia treatment
Cardiovascular events
Mortality

This study explores the potential benefits of vadadustat, an orally active hypoxia-inducible factor prolyl hydroxylase inhibitor, for the treatment of anemia in patients with chronic kidney disease (CKD). Vadaustat may offer advantages over erythropoiesis-stimulating agents due to its oral administration and potential for improved safety.

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

Comparison of darbepoetin alpha and recombinant human erythropoietin for treatment of anemia in pediatric chronic kidney disease: a non-inferiority trial from India.

Author: MazahirRufaida, AnandKanav, PruthiP K

Anemia treatment
CKD treatment
Injection site pain

This randomized controlled trial evaluated the non-inferiority of darbepoetin alpha (DA) compared to recombinant human erythropoietin (rHuEPO) for the treatment of anemia in children with chronic kidney disease (CKD) stage 3-5. DA was found to be non-inferior to rHuEPO with a comparable safety profile.

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

7.

Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.

Author: SinghAjay K, CarrollKevin, PerkovicVlado, SolomonScott, JhaVivekanand, JohansenKirsten L, LopesRenato D, MacdougallIain C, ObradorGregorio T, WaikarSushrut S, WannerChristoph, WheelerDavid C, WięcekAndrzej, BlackorbyAllison, CizmanBorut, CobitzAlexander R, DaviesRich, DoleJo, KlerLata, MeadowcroftAmy M, ZhuXinyi, McMurrayJohn J V,

hemoglobin increase
MI risk
stroke risk

This abstract discusses the use of hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors (PHIs) as an alternative to erythropoiesis-stimulating agents (ESAs) for treating anemia in patients with chronic kidney disease (CKD). PHIs have been shown to be as effective as ESAs in increasing hemoglobin levels.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Equivalence TrialA clinical trial designed to show that a new treatment is equivalent in efficacy/safety to an existing treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

Hematopoietic Recovery using Multi-Cytokine Therapy in 8 Patients Presenting Radiation-Induced Myelosuppression after Radiological Accidents.

Author: BenderitterMarc, Herrera-ReyesEduardo, GigovYvan, SouleauBertrand, HuetChristelle, TrompierFrançois, FagotThierry, GrégoireEric, MalfusonJean Valère, Konopacki-PotetJohanna, BuglovaElena, LatailladeJean-Jacques, TamaratRadia, GourmelonPatrick, de RevelThierry

Radiation myelosuppression treatment

Radiation-induced myelosuppression is treated with supportive care and specific interventions, including hematopoietic growth factors injection and hematopoietic cell transplantation in severe cases. This report details the medical management of eight patients with accidental radiation exposure, highlighting the role of growth factor combinations in accelerating bone marrow recovery.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

9.

Topiramate and darbepoetin alpha ameliorate bilirubin-induced neuronal cell damage.

Author: BaysalB, TüzünF, YücesoyE, ÖzbalS, UğurB E, SonmezA, OlgunY, KirkimG, EvinH, DumanN, KumralA, YılmazO, OzkanH

Kernicterus treatment
Neurological dysfunction improvement

Darbepoetin alpha administration improved bilirubin-induced neurological dysfunction in an experimental model of kernicterus, while topiramate administration did not.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

10.

Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.

Author: AkizawaTadao, IwasakiManabu, YamaguchiYusuke, MajikawaYoshikatsu, ReuschMichael

Maintained hemoglobin
Noninferior to darbepoetin alfa

Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, was found to be noninferior to darbepoetin alfa in maintaining hemoglobin levels within a target range of 10-12 g/dl in patients on hemodialysis for chronic kidney disease (CKD) anemia. The study involved 303 patients and lasted 24 weeks. Treatment-emergent adverse events were consistent with previous reports.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Equivalence TrialA clinical trial designed to show that a new treatment is equivalent in efficacy/safety to an existing treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

11.

Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial.

Author: SinhaShubhadeep D, BandiVamsi Krishna, BheemareddyBala Reddy, ThakurPankaj, CharySreenivasa, MehtaKalpana, PinnamareddyVikranth Reddy, PandeyRajendra, SreepadaSubhramanyam, DurugkarSantosh

Renal anemia treatment

Darbepoetin alfa, a long-acting erythropoiesis-stimulating glycoprotein, showed similar efficacy to erythropoietin alfa in treating renal anemia but with a longer duration of action, potentially offering a more convenient treatment option.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

13.

Comparison of the Pharmacokinetic-Pharmacodynamic Relationships of Two Darbepoetin Alfa Formulations in Healthy Male Volunteers.

Author: KimSeokuee, HongTaegon, KoJae-Wook, HuhWooseong, KimJung-Ryul

This study compared the pharmacokinetic (PK), pharmacodynamic (PD), and safety properties of the test (CJ-40001) and reference (NESP<sup>&#174;</sup>) versions of darbepoetin alfa.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

14.

T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF.

Author: AbraityteAurelija, AukrustPål, KouLei, AnandInder S, YoungJames, McmurrayJohn J V, van VeldhuisenDirk J, GullestadLars, UelandThor

This study investigated the predictive value of circulating markers reflecting monocyte/macrophage and T-cell activity on clinical outcomes in heart failure patients with reduced ejection fraction (HFrEF).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

15.

Real-world utilization of darbepoetin alfa in cancer chemotherapy patients.

Author: PanXiaoyun Lucy, NordstromBeth L, MacLachlanSharon, LinJunji, XuHairong, SharmaAnjali, ChandlerDavid, LiXiaoyan Shawn

Anemia treatment

The average weekly darbepoetin alfa dose among metastatic cancer patients with chemotherapy-induced anemia was 110 µg, which was lower than the labeled dosage for most adults.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

16.

Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease.

Author: SaglimbeneValeria M, PalmerSuetonia C, RuospoMarinella, NatalePatrizia, CraigJonathan C, StrippoliGiovanni Fm

Anemia treatment
Chronic kidney disease treatment
Cardiovascular events
Mortality

CERA, a newer, longer-acting erythropoiesis-stimulating agent (ESA), may offer advantages over other ESAs, such as epoetin or darbepoetin, due to its lower frequency of administration. However, different dosing requirements and molecular characteristics of CERA may lead to different health outcomes in people with anemia and chronic kidney disease (CKD).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

17.

Effects of long- and short-term darbepoetin-α treatment on oxidative stress, inflammation and endothelial injury in ApoE knockout mice.

Author: ÖzdemirEvrim Dursun, HanikogluAysegul, CortAysegul, OzbenBeste, SuleymanlarGultekin, OzbenTomris

Reduced oxidative stress
No effect on inflammation

Darbepoetin-α significantly decreased oxidative stress markers in ApoE-/- mice, but had no marked effects on inflammation and endothelial injury.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

20.

Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis.

Author: HondaHirokazu, KobayashiYasuna, OnumaShoko, ShibagakiKeigo, YuzaToshitaka, HiraoKeiichi, YamamotoToshinori, TomosugiNaohisa, ShibataTakanori

This study investigated the relationship between erythroferrone (ERFE), a regulator of hepcidin, and biomarkers of erythropoiesis and iron metabolism. The study also examined the effects of erythropoiesis-stimulating agents on ERFE production in patients on hemodialysis.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

21.

Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis Patients.

Author: BarbieriCarlo, BolzoniElena, MariFlavio, CattinelliIsabella, BellocchioFrancesco, MartinJosé D, AmatoClaudia, StopperAndrea, GattiEmanuele, MacdougallIain C, StuardStefano, CanaudBernard

Anemia management

This study developed a predictive model to help anticipate the long-term response to erythropoiesis-stimulating agents (ESAs) and iron therapy in hemodialysis patients. The model, based on an artificial neural network, was able to predict hemoglobin levels three months into the future with reasonable accuracy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

22.

Preschool Assessment of Preterm Infants Treated With Darbepoetin and Erythropoietin.

Author: OhlsRobin K, CannonDaniel C, PhillipsJohn, CaprihanArvind, PatelShrena, WinterSarah, SteffenMichael, YeoRonald A, CampbellRichard, WiedmeierSusan, BakerShawna, GonzalesSean, LoweJean

Cognitive outcomes
Developmental improvement

Infants treated with erythropoiesis-stimulating agents (ESAs) had better cognitive outcomes and less developmental impairment at 3.5 to 4 years of age compared to those receiving placebo. This suggests that ESAs may improve long-term cognitive outcomes in preterm infants.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Language : English

23.

Randomized Controlled Trial of Darbepoetin α Versus Continuous Erythropoietin Receptor Activator Injected Subcutaneously Once Every Four Weeks in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage.

Author: FurukawaTetsuya, OkadaKazuyoshi, AbeMasanori, TeiRitsukou, OikawaOsamu, MaruyamaNoriaki, MaruyamaTakashi

CKD treatment
Hb level stability
Target Hb achievement

This study compared two drugs, CERA and DA, that are used to increase hemoglobin levels in people with kidney disease. Both drugs were effective in increasing hemoglobin levels, and there were no significant differences between the two groups.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

24.

Effects of long-acting erythropoietin analog darbepoetin-α on adriamycin-induced chronic nephropathy.

Author: HusseinAbdelaziz M, EldosokyMohamed, HandhleAhmed, ElserougyHanaa, SarhanMohamed, SobhMohamed A, HussinyMahmoud El, El NasharEman M

Improved kidney function
Reduced oxidative stress

Darbepoetin-α (DPO-α) was found to alleviate adriamycin (ADR)-induced chronic nephropathy in rats.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

25.

Satellite cell response to erythropoietin treatment and endurance training in healthy young men.

Author: HoedtAndrea, ChristensenBritt, NellemannBirgitte, MikkelsenUlla Ramer, HansenMette, SchjerlingPeter, FarupJean

Improved muscle growth
Increased MyoD
SC proliferation
Long-term Epo impact on SCs

Erythropoietin (Epo) treatment stimulates satellite cell (SC) proliferation in vitro and endurance training does so in vivo. This study investigates the effects of Epo treatment and endurance training on SCs in healthy young men, finding that Epo treatment increases MyoD(+) SC content and that Epo receptors are expressed in human SCs.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.